Shawn Fatholahi
Seminars
Thursday 28th January 2027
Advancing Triple Monoamine Reuptake Inhibition as a Novel Non-Opioid Approach for Acute & Chronic Pain
11:30 am
- Reviewing the development of MAX-001, an optimized nefopam formulation designed to deliver rapid onset and extended analgesia without opioids or NSAIDs
- Exploring how preferential norepinephrine reuptake inhibition may modulate pain signalling across acute and chronic pain settings
- Translating Phase 1 safety and pharmacokinetic findings into future clinical development strategies for acute and chronic pain indications
- Positioning triple monoamine reuptake inhibition within the evolving landscape of next-generation non-opioid analgesics
